4-Fluoro-3-nitrobenzoic acid | CAS:453-71-4

We serve 4-Fluoro-3-nitrobenzoic acid CAS:453-71-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Fluoro-3-nitrobenzoic acid

Chemical Name:4-Fluoro-3-nitrobenzoic acid
CAS.NO:453-71-4
Synonyms:4-Fluoro-3-nitrobenzoic acid
5-Carboxy-2-fluoronitrobenzene
4-fluoro-5-nitrobenzoic acid
3-Nitro-4-fluorobenzoic acid
p-Fluoro-3-nitrobenzoic acid
p-fluoro-m-nitrobenzoic acid
Molecular Formula:C7H4FNO4
Molecular Weight:185.10900
 
Physical and Chemical Properties:
Density:1.568
Melting point:125-128ºC
Index of Refraction:1.588
 
Specification:
Appearance:Pale yellow powder
Assay:≥99.0%
Moisture:≤0.2%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 4-Fluoro-3-nitrobenzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,p-fluoro-m-nitrobenzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Carboxy-2-fluoronitrobenzene Use and application,5-Carboxy-2-fluoronitrobenzene technical grade,usp/ep/jp grade.


Related News: This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire.2-chloro-6-(ethylamino)-4-nitrophenol manufacturer This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire.1-Phenylcyclopentanecarboxylic acid supplier This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire.Methyl Methoxyacetate vendor Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.